Abstract:We read the study by Durila et al 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar with interest; however, we seek several clarifications. First, a separate study by Yu et al 2 Yu ES, Jeon MJ, Kang KW, et al. The role of platelet function analyzer-200 in predicting perioperative bleeding risk [e-pub ahead of print]. Korean J Intern Med. doi:10.3904/kjim.2019.112, accessed September 9, 2020. Google Scholar showed that the results of platelet function analyzer 200 (PFA 200) are influenced by various factors, such as the use of aspirin and other non-steroidal anti-inflammatory agents, blood group type, hematocrit and time of blood collection, transfusions, and underlying diseases. The severity of surgery might cause bleeding, which affects collagen–epinephrine and collagen–adenosine diphosphate. The conclusion that the pathology of primary hemostasis detected by the PFA 200 (collagen–epinephrine and collagen–adenosine diphosphate) was specific for the extracorporeal membrane oxygenation (ECMO) phase of surgery is not robust and is subject to confounding bias. 3 Zhang Z Model building strategy for logistic regression: purposeful selection. Ann Transl Med. 2016; 4: 111 Crossref PubMed Scopus (192) Google Scholar Second, a continuous intravenous infusion of low-molecular-weight heparin was used to prevent venous thromboprophylaxis, but without dose described. Piwowarczyk et al 4 Piwowarczyk P, Borys M, Kutnik P, et al. Unfractionated heparin versus subcutaneous nadroparin in adults supported with venovenous extracorporeal membrane oxygenation: a retrospective, multicenter study [e-pub ahead of print]. ASAIO J. doi:10.1097/MAT.0000000000001166, accessed September 9, 2020. Google Scholar compared nadroparin with unfractionated heparin during veno-venous ECMO and found no significant difference in the number of thrombotic and hemorrhagic events. In the paper by Durila et al, 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar even with the use of continuous intravenous infusion of low-molecular-weight heparin, 2 patients suffered thrombotic events. Third, the duration of the ECMO in their work is short (5 ± 3 days). The effect of duration of support on outcomes was not provided because we would suggest that the risk of thrombotic events is lower with a shorter duration of ECMO support. Given these considerations, it is difficult for us to completely agree with the conclusion that the PFA 200 analyzer may be used to prevent circuit thrombosis instead of using unfractionated heparin in patients on prolonged ECMO. We believe that a point-of-care test such as the PFA 200 may assist in adjusting anti-coagulant strategy to potentially reduce the use of unfractionated heparin rather than to prevent circuit thrombosis and obviate the use of unfractionated heparin altogether, especially in patients on prolonged ECMO support.

Platelet volume indices and von Willebrand factor levels in blood exposed to polymer- or heparin-coated membrane oxygenators

Hemostasis During Extracorporeal Membrane Oxygenation: More Questions

Designing an experimental method for assessing biocompatibility of circuit coatings using biomarkers for platelet activation during cardiopulmonary bypass

Investigation of the role of von Willebrand factor in shear-induced platelet activation and functional alteration under high non-physiological shear stress

Protective Effect of Platelets Transfusion During Extracorporeal Circulation

Impact of surface coating and systemic anticoagulants on hemostasis and inflammation in a human whole blood model

Correlation between the extent of platelet activation in platelet concentrates and in vitro and in vivo parameters

Impact of extracorporeal membrane oxygenation treatments on acquired von Willebrand syndrome in patients with out-of-hospital cardiac arrest: a retrospective observational study

An in Vitro Study of the Adhesion of Blood Platelets Onto Vascular Catheters. Part I

In vitro study on device‐induced damage to blood cellular components and degradation of von Willebrand factor in a CentriMag pump‐assisted circulation

Platelet count reduction during in vitro membrane oxygenation affects platelet activation, neutrophil extracellular trap formation and clot stability, but does not prevent clotting

Effect of Endothelial Culture Medium Composition on Platelet Responses to Polymeric Biomaterials

Influence of a Preadsorbed Terpolymer on Human Platelet Accumulation, Fibrinogen Adsorption, and Ex Vivo Blood Activation in Hemodialysis Hollow Fibers

Multi-Method Investigation of Blood Damage Induced by Blood Pumps in Different Clinical Support Modes

Synergistic effect of shear and ADP on platelet growth on ZTA and Ti6Al4V surfaces

[Influence of Biomateriai on Focal Adhesion Kinase of Platelet: Ex Vivo Study].

Volume Regulation and Nonosmotic Volume of Individual Human Platelets Quantified by High-Speed Scanning Ion Conductance Microscopy

[In Vitro Evaluation of the Function of Sheet Biomaterials in Platelet Activation].

In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices

The early decline in platelet count is associated with increased adverse outcomes in non heparin-induced thrombocytopenia pediatric patients undergoing VA-ECMO

Temporal Changes in the Surface Chemistry and Topography of Reactive Ion Plasma-Treated Poly(vinyl alcohol) Alter Endothelialization Potential